Dr. Paul Muchowski
CEO & CSO, Defined Concentrates
2:45 PM - 3:45 PM - A Look Into the Future: An FDA Regulatory Framework for Hemp/CBD
11:15 AM - 12:15 PM - The Latest Developments in Medical Cannabis Research
Paul Muchowski received a PhD in Biological Structure from the University of Washington and performed post-doctoral training at the Max Planck Institute for Biochemistry. Dr. Muchowski worked as a professor in the medical schools at the University of Washington and the University of California San Francisco, and subsequently in drug development in the pharmaceutical and biotech industries. Dr. Muchowski's research focuses on the molecular basis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Huntington's disease. He has published >60 highly cited research papers. His lab also published research on the role of the endocannabinoid system in neurodegeneration, showing that it is a critical determinant of the onset and severity of disease in animal models of chronic neurodegeneration. His lab developed potential therapies for major neurodegenerative diseases that led to the founding of the biotech company KynuRex. Dr. Muchowski currently serves as the CEO and CSO for Defined Concentrates (DBA Dr. Paul's).